Literature DB >> 8287315

Decrease of serum calcium concentration and lost influence of calcium on parathyroid hormone release in a patient with primary hyperparathyroidism after treatment with diphosphonates.

H Kotzmann1, P Bernecker, T Svoboda, B Niederle, A Luger.   

Abstract

Prolonged decrease of elevated serum calcium levels after treatment with diphosphonates in patients with primary hyperparathyroidism (pHPT) is very rare. A patient with water clear cell hyperplasia and five enlarged glands is presented who received diphosphonates (day 1 through day 8 dichloromethylene diphosphonate orally and a single dose of 60 mg pamidronate on day 8 intravenously) leading to a significant fall in serum calcium levels. Surprisingly, there was no reactive increase in intact parathyroid hormone (PTH) in the following 18 days. Patients with missing PTH regulation to hypocalcemia after diphosphonates who need a period of stabilization prior to parathyroid surgery might benefit most from this therapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8287315     DOI: 10.1007/BF01351832

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  25 in total

1.  Regulation of parathyroid hormone secretion by calcium in patients with parathyroid adenoma.

Authors:  E Ishimura; T Miki; K Harada; K Hiratani; K Nakatsuka; Y Nishizawa; H Morii
Journal:  Horm Metab Res       Date:  1992-02       Impact factor: 2.936

2.  Serum osteocalcin levels in primary hyperparathyroidism.

Authors:  P Pietschmann; B Niederle; A Anvari; W Woloszczuk
Journal:  Klin Wochenschr       Date:  1991-05-24

3.  Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia.

Authors:  S H Ralston; S J Gallacher; U Patel; F J Dryburgh; W D Fraser; R A Cowan; I T Boyle
Journal:  Lancet       Date:  1989-11-18       Impact factor: 79.321

4.  Acute parathyroid hormone secretory dynamics: hormone secretion from normal primate and adenomatous human tissue in response to changes in extracellular calcium concentration.

Authors:  E Orwoll; N Kane-Johnson; J Cook; L Roberts; L Strasik; M McClung
Journal:  J Clin Endocrinol Metab       Date:  1986-05       Impact factor: 5.958

5.  Regulation of parathyroid hormone release in primary and secondary hyperparathyroidism - studies in vivo and in vitro.

Authors:  C Rudberg; G Akerström; S Ljunghall; L Grimelius; H Johansson; H Pertoft; L Wide
Journal:  Acta Endocrinol (Copenh)       Date:  1982-11

6.  Aminopropylidine diphosphonate (APD) in mild primary hyperparathyroidism: effect on clinical status.

Authors:  R S Schmidli; I Wilson; E A Espiner; A M Richards; R A Donald
Journal:  Clin Endocrinol (Oxf)       Date:  1990-03       Impact factor: 3.478

7.  A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone.

Authors:  D Thiébaud; P Jaeger; C Gobelet; A F Jacquet; P Burckhardt
Journal:  Am J Med       Date:  1988-08       Impact factor: 4.965

8.  Biochemical and clinical responses to dichloromethylene diphosphonate (Cl2MDP) in Paget's disease of bone.

Authors:  D L Douglas; T Duckworth; J A Kanis; C Preston; D J Beard; T W Smith; I Underwood; J S Woodhead; R G Russell
Journal:  Arthritis Rheum       Date:  1980-10

9.  Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).

Authors:  F J van Breukelen; O L Bijvoet; A T van Oosterom
Journal:  Lancet       Date:  1979-04-14       Impact factor: 79.321

10.  The use of dichloromethylene bisphosphonate and aminobutane bisphosphonate in hypercalcemia of malignancy.

Authors:  S Adami; G P Bolzicco; A Rizzo; G Salvagno; F Bertoldo; M Rossini; R Suppi; V Lo Cascio
Journal:  Bone Miner       Date:  1987-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.